Bratislava Statement: consensus recommendations for improving pancreatic cancer care.


Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
11 2020
Historique:
received: 15 09 2020
accepted: 07 10 2020
entrez: 14 11 2020
pubmed: 15 11 2020
medline: 20 7 2021
Statut: ppublish

Résumé

Pancreatic cancer is one of the most lethal tumours, and it is the fourth cause of cancer death in Europe. Despite its important public health impact, no effective treatments exist, nor are there high-visibility research efforts to improve care. This alarming situation is emblematic of a larger group of cancer diseases, known as neglected cancers. To address the impact of these diseases, the European Commission-supported Innovative Partnership for Action Against Cancer launched a multi-stakeholder initiative to determine key steps that healthcare systems can rapidly implement to improve their response. A working group comprising 20 representatives from European medical societies, patient associations, cancer plan organisations and other relevant European healthcare stakeholders was organised. A consensus process based on the results of different studies, discussion of research outcomes, and development and endorsement of draft statements resulted in 22 consensus recommendations (the Bratislava Statement). The statement argues that substantial improvements can be achieved in patient outcomes by centralising pancreatic cancer care around state-of-the-art reference centres, staffed by expert multidisciplinary teams capable of providing high-quality care. This organisational model requires a specific care framework encompassing primary, palliative and survivorship care, and a policy environment prioritising the use of quality criteria and performance assessments as well as research investments dedicated to prevention, risk prediction, early detection and diagnosis. In order to address the challenges posed by neglected cancers in general and pancreatic cancer in particular, a specific control strategy tailored to this reality is required.

Identifiants

pubmed: 33188052
pii: S2059-7029(20)32761-7
doi: 10.1136/esmoopen-2020-001051
pmc: PMC7668355
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e001051

Informations de copyright

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Joan Prades (J)

Catalonian Cancer Strategy, Department of Health, Barcelona, Spain; University of Barcelona (IDIBELL), Barcelona, Spain. Electronic address: jlprades@iconcologia.net.

Dirk Arnold (D)

Med. Onkologie, Tumorzentrum Hamburg, AK Altona, Hamburg, Germany; European Society of Medical Oncology (ESMO), Lugano, Ticino, Switzerland.

Thomas Brunner (T)

Department of Radiation Oncology, University of Magdeburg, Magdeburg, Germany; European Society for Radiotherapy & Oncology (ESTRO), Brussels, Belgium.

Antonella Cardone (A)

Pancreatic Cancer Europe, Brussels, Belgium; European Cancer Patient Coalition (ECPC), Brussels, Belgium.

Alfredo Carrato (A)

Pancreatic Cancer Europe, Brussels, Belgium; IRYCIS, CIBERONIC, Madrid, Spain.

Cristina Coll-Ortega (C)

Catalonian Cancer Strategy, Department of Health, Barcelona, Spain.

Samuel De Luze (S)

Institut National du Cancer, Billancourt, Île-de-France, France.

Pascal Garel (P)

European Hospital and Healthcare Federation, Brussels, Belgium.

Maria E Goossens (ME)

Cancer Centre-OD Public Health and Surveillance, Sciensano, Brussels, Belgium.

Roberto Grilli (R)

Azienda USL-IRCCS of Reggio Emilia, Bologna, Italy.

Meggan Harris (M)

Independent Researcher, Valencia, Spain.

Marleen Louagie (M)

Belgian National Institute for Health and Disability Insurance, Brussels, Belgium.

Núria Malats (N)

Pancreatic Cancer Europe, Brussels, Belgium; Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.

Pamela Minicozzi (P)

London School of Hygiene & Tropical Medicine, London, UK; Analytical Epidemiology and Health Impact Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Stefano Partelli (S)

Università Vita Salute San Raffaele, Milano, Lombardia, Italy; European Society of Surgical Oncology (ESSO), Brussels, Belgium.

Silvia Pastorekova (S)

Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

Marius Petrulionis (M)

Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania; Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Richard Price (R)

The European Cancer Organisation (ECCO), Brussels, Belgium.

Francesco Sclafani (F)

Department of Medical Oncology, Institut Jules Bordet, Bruxelles, Belgium; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Bozena Smolkova (B)

Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

Josep M Borras (JM)

Catalonian Cancer Strategy, Department of Health, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalunya, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH